Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington’s disease

Bibliography

• Allbutt C. Notes from a clinical lecture on a case of huntington’s chorea: delivered at Addenbrooke’s Hospital, Cambridge. Br Med J 1918;1:389-90
   PubMedGoogle Scholar
• Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10:83-98
   PubMed Web of Science ®Google Scholar
• Piira A, van Walsem MR, Mikalsen G, et al. Effects of a one year intensive multidisciplinary rehabilitation program for patients with Huntington’s disease: a prospective intervention study. PLoS Curr 2013;5
   PubMedGoogle Scholar
• Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 1983;306:234-8
   PubMed Web of Science ®Google Scholar
• The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993;72:971-83
   PubMed Web of Science ®Google Scholar
• Aziz NA, van Belzen MJ, Coops ID, et al. Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington’s disease. Eur J Med Genet 2011;54:e413-18
   Web of Science ®Google Scholar
• Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci USA 2004;101:3498-503
   PubMed Web of Science ®Google Scholar
• Andresen JM, Gayan J, Cherny SS, et al. Replication of twelve association studies for Huntington’s disease residual age of onset in large Venezuelan kindreds. J Med Genet 2007;44:44-50
   PubMed Web of Science ®Google Scholar
• Andre VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington’s disease: a balancing act. CNS Neurosci Ther 2010;16:163-78
   PubMed Web of Science ®Google Scholar
• Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington’s disease. Mov Disord 1996;11:273-7
   PubMed Web of Science ®Google Scholar
• O’Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003;60:996-8
   PubMed Web of Science ®Google Scholar
• Caviston JP, Holzbaur EL. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 2009;19:147-55
   PubMed Web of Science ®Google Scholar
• Hodges A, Strand AD, Aragaki AK, et al. Regional and cellular gene expression changes in human Huntington’s disease brain. Hum Mol Genet 2006;15:965-77
   PubMed Web of Science ®Google Scholar
• Nasir J, Floresco SB, O’Kusky JR, et al. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995;81:811-23
   PubMed Web of Science ®Google Scholar
• Li JY, Plomann M, Brundin P. Huntington’s disease: a synaptopathy? Trends Mol Med 2003;9:414-20
   PubMed Web of Science ®Google Scholar
• Jarabek BR, Yasuda RP, Wolfe BB. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington’s mouse model. Brain 2004;127:505-16
   PubMed Web of Science ®Google Scholar
• Lim D, Fedrizzi L, Tartari M, et al. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem 2008;283:5780-9
   PubMed Web of Science ®Google Scholar
• Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci 2008;27:2803-20
   PubMed Web of Science ®Google Scholar
• Ehrlich ME. Huntington’s disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics 2012;9:270-84
   PubMed Web of Science ®Google Scholar
• Bolam JP, Hanley JJ, Booth PA, et al. Synaptic organisation of the basal ganglia. J Anat 2000;196(Pt 4):527-42
   PubMed Web of Science ®Google Scholar
• Reiner A, Albin RL, Anderson KD, et al. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 1988;85:5733-7
   PubMed Web of Science ®Google Scholar
• Albin RL, Reiner A, Anderson KD, et al. Striatal and nigral neuron subpopulations in rigid Huntington’s disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol 1990;27:357-65
   PubMed Web of Science ®Google Scholar
• Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-48
   PubMed Web of Science ®Google Scholar
• Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506
   PubMed Web of Science ®Google Scholar
• Gray M, Shirasaki DI, Cepeda C, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 2008;28:6182-95
   Google Scholar
• Slow EJ, van Raamsdonk J, Rogers D, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003;12:1555-67
   PubMed Web of Science ®Google Scholar
• Menalled LB, Sison JD, Wu Y, et al. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington’s disease knock-in mice. J Neurosci 2002;22:8266-76
   PubMed Web of Science ®Google Scholar
• Wheeler VC, White JK, Gutekunst CA, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 2000;9:503-13
   PubMed Web of Science ®Google Scholar
• Menalled L, El-Khodor BF, Patry M, et al. Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models. Neurobiol Dis 2009;35:319-36
   PubMed Web of Science ®Google Scholar
• Lin CH, Tallaksen-Greene S, Chien WM, et al. Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet 2001;10:137-44
   PubMedGoogle Scholar
• Woodman B, Butler R, Landles C, et al. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull 2007;72:83-97
   PubMed Web of Science ®Google Scholar
• Li XJ, Li S. Influence of species differences on the neuropathology of transgenic Huntington’s disease animal models. J Genet Genomics 2012;39:239-45
   PubMed Web of Science ®Google Scholar
• Marsh JL, Walker H, Theisen H, et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 2000;9:13-25
   PubMed Web of Science ®Google Scholar
• Agrawal N, Pallos J, Slepko N, et al. Identification of combinatorial drug regimens for treatment of Huntington’s disease using Drosophila. Proc Natl Acad Sci USA 2005;102:3777-81
   PubMed Web of Science ®Google Scholar
• Hsu AL, Murphy CT, Kenyon C. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 2003;300:1142-5
   PubMed Web of Science ®Google Scholar
• Haldimann P, Muriset M, Vigh L, et al. The novel hydroxylamine derivative NG-094 suppresses polyglutamine protein toxicity in Caenorhabditis elegans. J Biol Chem 2011;286:18784-94
   PubMed Web of Science ®Google Scholar
• Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57:369-84
   PubMed Web of Science ®Google Scholar
• Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004;10(Suppl):S10-17
   PubMedGoogle Scholar
• Ribeiro FM, Devries RA, Hamilton A, et al. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington’s disease. Human Mol Genet 2013; doi: 10.1093/hmg/ddt598
   PubMed Web of Science ®Google Scholar
• Miller J, Arrasate M, Shaby BA, et al. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington’s disease molecular pathogenesis. J Neurosci 2010;30:10541-50
   PubMed Web of Science ®Google Scholar
• Williams A, Sarkar S, Cuddon P, et al. Novel targets for Huntington’s disease in an mTOR-independent autophagy pathway. Nat Chem Biol 2008;4:295-305
   PubMed Web of Science ®Google Scholar
• Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431:805-10
   PubMed Web of Science ®Google Scholar
• Giacomello M, Oliveros JC, Naranjo JR, et al. Neuronal Ca(2+) dyshomeostasis in Huntington disease. Prion 2013;7:76-84
   PubMed Web of Science ®Google Scholar
• Chen N, Luo T, Wellington C, et al. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 1999;72:1890-8
   PubMed Web of Science ®Google Scholar
• Tang TS, Tu H, Chan EY, et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003;39:227-39
   PubMed Web of Science ®Google Scholar
• Tang TS, Slow E, Lupu V, et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington’s disease. Proc Natl Acad Sci USA 2005;102:2602-7
   PubMed Web of Science ®Google Scholar
• Panov AV, Gutekunst CA, Leavitt BR, et al. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 2002;5:731-6
   PubMed Web of Science ®Google Scholar
• Choo YS, Johnson GV, MacDonald M, et al. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 2004;13:1407-20
   PubMed Web of Science ®Google Scholar
• Seong IS, Ivanova E, Lee JM, et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 2005;14:2871-80
   PubMed Web of Science ®Google Scholar
• Brustovetsky N, LaFrance R, Purl KJ, et al. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington’s Disease. J Neurochem 2005;93:1361-70
   PubMed Web of Science ®Google Scholar
• Zuccato C, Tartari M, Crotti A, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003;35:76-83
   PubMed Web of Science ®Google Scholar
• Kang H, Schuman EM. Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science 1995;267:1658-62
   PubMed Web of Science ®Google Scholar
• Figurov A, Pozzo-Miller LD, Olafsson P, et al. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 1996;381:706-9
   PubMed Web of Science ®Google Scholar
• Canals JM, Pineda JR, Torres-Peraza JF, et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington’s disease. J Neurosci 2004;24:7727-39
   PubMed Web of Science ®Google Scholar
• Seredenina T, Luthi-Carter R. What have we learned from gene expression profiles in Huntington’s disease? Neurobiol Dis 2012;45:83-98
   PubMed Web of Science ®Google Scholar
• Luthi-Carter R, Hanson SA, Strand AD, et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 2002;11:1911-26
   PubMed Web of Science ®Google Scholar
• DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington’s disease. Trends Neurosci 1990;13:286-9
   PubMed Web of Science ®Google Scholar
• Ribeiro FM, Paquet M, Cregan SP, et al. Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS Neurol Disord Drug Targets 2010;9:574-95
   Google Scholar
• Nakanishi S. Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity. Neuron 1994;13:1031-7
   PubMed Web of Science ®Google Scholar
• Calabresi P, Centonze D, Pisani A, et al. Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington’s disease. Exp Neurol 1999;158:97-108
   PubMed Web of Science ®Google Scholar
• Ribeiro FM, Paquet M, Ferreira LT, et al. Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington’s disease. J Neurosci 2010;30:316-24
   PubMed Web of Science ®Google Scholar
• Paquet M, Ribeiro FM, Guadagno J, et al. Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose deprivation-mediated astrocyte apoptosis. Mol Brain 2013;6:9
   PubMed Web of Science ®Google Scholar
• Balazs R, Miller S, Romano C, et al. Metabotropic glutamate receptor mGluR5 in astrocytes: pharmacological properties and agonist regulation. J Neurochem 1997;69:151-63
   PubMed Web of Science ®Google Scholar
• Shigemoto R, Nomura S, Ohishi H, et al. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 1993;163:53-7
   PubMed Web of Science ®Google Scholar
• Testa CM, Standaert DG, Young AB, et al. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J Neurosci 1994;14:3005-18
   PubMed Web of Science ®Google Scholar
• Bordi F, Ugolini A. Group I metabotropic glutamate receptors: implications for brain diseases. Prog Neurobiol 1999;59:55-79
   PubMed Web of Science ®Google Scholar
• Dhami GK, Ferguson SS. Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacol Ther 2006;111:260-71
   PubMed Web of Science ®Google Scholar
• Choe ES, Wang JQ. Group I metabotropic glutamate receptors control phosphorylation of CREB, Elk-1 and ERK via a CaMKII-dependent pathway in rat striatum. Neurosci Lett 2001;313:129-32
   PubMed Web of Science ®Google Scholar
• Nicodemo AA, Pampillo M, Ferreira LT, et al. Pyk2 uncouples metabotropic glutamate receptor G protein signaling but facilitates ERK1/2 activation. Mol Brain 2010;3:4
   PubMed Web of Science ®Google Scholar
• Ribeiro FM, Ferreira LT, Paquet M, et al. Phosphorylation-independent regulation of metabotropic glutamate receptor 5 desensitization and internalization by G protein-coupled receptor kinase 2 in neurons. J Biol Chem 2009;284:23444-53
   Google Scholar
• Pisani A, Calabresi P, Centonze D, et al. Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 1997;120:1007-14
   PubMed Web of Science ®Google Scholar
• Wu J, Rush A, Rowan MJ, et al. NMDA receptor- and metabotropic glutamate receptor-dependent synaptic plasticity induced by high frequency stimulation in the rat dentate gyrus in vitro. J Physiol 2001;533:745-55
   PubMed Web of Science ®Google Scholar
• Hou L, Klann E. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J Neurosci 2004;24:6352-61
   PubMed Web of Science ®Google Scholar
• Mao L, Yang L, Tang Q, et al. The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons. J Neurosci 2005;25:2741-52
   PubMed Web of Science ®Google Scholar
• Ribeiro FM, Pires RG, Ferguson SS. Huntington’s disease and Group I metabotropic glutamate receptors. Mol Neurobiol 2011;43:1-11
   Google Scholar
• Dhami GK, Anborgh PH, Dale LB, et al. Phosphorylation-independent regulation of metabotropic glutamate receptor signaling by G protein-coupled receptor kinase 2. J Biol Chem 2002;277:25266-72
   PubMed Web of Science ®Google Scholar
• Dhami GK, Babwah AV, Sterne-Marr R, et al. Phosphorylation-independent regulation of metabotropic glutamate receptor 1 signaling requires g protein-coupled receptor kinase 2 binding to the second intracellular loop. J Biol Chem 2005;280:24420-7
   PubMed Web of Science ®Google Scholar
• Anborgh PH, Godin C, Pampillo M, et al. Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin. J Biol Chem 2005;280:34840-8
   PubMed Web of Science ®Google Scholar
• Esseltine JL, Ribeiro FM, Ferguson SS. Rab8 modulates metabotropic glutamate receptor subtype 1 intracellular trafficking and signaling in a protein kinase C-dependent manner. J Neurosci 2012;32:16933-42a
   Google Scholar
• Schoepp DD, Goldsworthy J, Johnson BG, et al. 3,5-dihydroxyphenylglycine is a highly selective agonist for phosphoinositide-linked metabotropic glutamate receptors in the rat hippocampus. J Neurochem 1994;63:769-72
   PubMed Web of Science ®Google Scholar
• Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999;38:1431-76
   PubMed Web of Science ®Google Scholar
• Eaton SA, Jane DE, Jones PL, et al. Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-alpha-methyl-4-carboxyphenylglycine. Eur J Pharmacol 1993;244:195-7
   PubMed Web of Science ®Google Scholar
• Varney MA, Cosford ND, Jachec C, et al. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 1999;290:170-81
   PubMed Web of Science ®Google Scholar
• O’Leary DM, Movsesyan V, Vicini S, et al. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol 2000;131:1429-37
   PubMed Web of Science ®Google Scholar
• Cosford ND, Roppe J, Tehrani L, et al. [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 2003;13:351-4
   PubMed Web of Science ®Google Scholar
• Lindemann L, Jaeschke G, Michalon A, et al. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther 2011;339:474-86
   PubMed Web of Science ®Google Scholar
• Mathiesen JM, Svendsen N, Brauner-Osborne H, et al. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 2003;138:1026-30
   PubMed Web of Science ®Google Scholar
• Lindsley CW, Wisnoski DD, Leister WH, et al. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem 2004;47:5825-8
   PubMed Web of Science ®Google Scholar
• de Paulis T, Hemstapat K, Chen Y, et al. Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J Med Chem 2006;49:3332-44
   PubMed Web of Science ®Google Scholar
• Sokol DK, Maloney B, Long JM, et al. Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology 2011;76:1344-52
   PubMed Web of Science ®Google Scholar
• Doherty AJ, Palmer MJ, Henley JM, et al. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 1997;36:265-7
   PubMed Web of Science ®Google Scholar
• Alagarsamy S, Saugstad J, Warren L, et al. NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin. Neuropharmacology 2005;49(Suppl 1):135-45
   PubMedGoogle Scholar
• Baskys A, Bayazitov I, Fang L, et al. Group I metabotropic glutamate receptors reduce excitotoxic injury and may facilitate neurogenesis. Neuropharmacology 2005;49(Suppl 1):146-56
   PubMedGoogle Scholar
• Bruno V, Battaglia G, Copani A, et al. An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors. Eur J Neurosci 2001;13:1469-78
   PubMed Web of Science ®Google Scholar
• Rong R, Ahn JY, Huang H, et al. PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat Neurosci 2003;6:1153-61
   PubMed Web of Science ®Google Scholar
• Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004;27:370-7
   PubMed Web of Science ®Google Scholar
• Westmark CJ, Malter JS. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 2007;5:e52
   PubMed Web of Science ®Google Scholar
• Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron 2003;37:925-37
   PubMed Web of Science ®Google Scholar
• Lee RK, Wurtman RJ, Cox AJ, et al. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci USA 1995;92:8083-7
   PubMed Web of Science ®Google Scholar
• Gray L, van den Buuse M, Scarr E, et al. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol 2009;12:45-60
   PubMed Web of Science ®Google Scholar
• Opitz T, Reymann KG. (1S, 3R)-ACPD protects synaptic transmission from hypoxia in hippocampal slices. Neuropharmacology 1993;32:103-4
   PubMed Web of Science ®Google Scholar
• Nicoletti F, Bockaert J, Collingridge GL, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 2011;60:1017-41
   PubMed Web of Science ®Google Scholar
• Vanderklish PW, Edelman GM. Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci USA 2002;99:1639-44
   PubMed Web of Science ®Google Scholar
• Um JW, Kaufman AC, Kostylev M, et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 2013;79:887-902
   PubMed Web of Science ®Google Scholar
• Ossowska K, Konieczny J, Wolfarth S, et al. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 2001;41:413-20
   PubMed Web of Science ®Google Scholar
• Schiefer J, Sprunken A, Puls C, et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington’s disease. Brain Res 2004;1019:246-54
   PubMed Web of Science ®Google Scholar
• Doria JG, Silva FR, de Souza JM, et al. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington’s disease. Br J Pharmacol 2013;169:909-21
   PubMed Web of Science ®Google Scholar
• Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012;74:49-56
   PubMed Web of Science ®Google Scholar